Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of TAK-491 in Healthy Chinese Subjects
NCT02541669Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of azilsartan medoxomil in hypertension (HTN) (5 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration at Day 10, Time to Reach Maximum Plasma Concentration at Day 10 and 2 more. Started Nov 2015; status: completed.
02
Drugs
azilsartan medoxomil
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02541669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02541669.